Leukemia Clinical Trials in Arizona

Showing 281-300 of 670 trials

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

NCT05775406

This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute lymphocytic leukemia (ALL), R/R lymphoma, myelofibrosis, and R/R solid tumors. The study will identify the pharmacologically optimal dose(s) (MTD) of KT-253 as the recommended Phase 2 dose (RP2D), based on all safety, PK, PD, and efficacy data.

Myeloid MalignanciesAcute Lymphocytic LeukemiaLymphomas+1 more

Kymera Therapeutics, Inc.52 participantsStarted May 2023

Scottsdale, Arizona, United States • Sacramento, California, United States • Boston, Massachusetts, United States +8 more locations

AVAILABLE33 miles

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

NCT05776134

The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.

Mantle Cell LymphomaAcute Lymphoblastic Leukemia

Kite, A Gilead Company

Birmingham, Alabama, United States • Gilbert, Arizona, United States • Duarte, California, United States +41 more locations

PreviousPage 15 of 34Next

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Leukemia Trials in Other Cities

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

MIRACLE of LIFE Study

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Other Conditions in Arizona